Floatz logo

Ava-6000 (Fap-Activated Doxorubicin Prodrug)

Soft Tissue Sarcoma

Avacta Life Sciences LtdSmall moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

101 Active assets in the Soft Tissue Sarcoma cohort.

Asset / SponsorPhaseRating
Palbociclib
Brown University
Phase 2BB
Oxaliplatin
OHSU Knight Cancer Institute
Phase 2BB
Nivestim
University of California, Irvine
Phase 3BB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 2BB
Dacarbazine
Institut Bergonié
Phase 3BB

View all 50 →

Same molecule, other indications

Ava-6000 (Fap-Activated Doxorubicin Prodrug) is also rated in:

tumor of salivary glandActive
CC
Indicative · Phase 1
43 / 100
View asset →
ovarian carcinomaActive
CC
Indicative · Phase 1
41 / 100
View asset →
urothelial carcinomaActive
C
Indicative · Phase 1
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →